Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Fundamental Analysis

NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD

4.2  -0.14 (-3.23%)

After market: 4.4493 +0.25 (+5.94%)

Fundamental Rating

2

Overall UNCY gets a fundamental rating of 2 out of 10. We evaluated UNCY against 553 industry peers in the Biotechnology industry. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UNCY is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

UNCY had negative earnings in the past year.
In the past year UNCY has reported a negative cash flow from operations.
UNCY had negative earnings in each of the past 5 years.
UNCY had a negative operating cash flow in each of the past 5 years.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of UNCY (-119.44%) is worse than 80.11% of its industry peers.
With a Return On Equity value of -509.00%, UNCY is not doing good in the industry: 78.12% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROIC N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UNCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

5

2. Health

2.1 Basic Checks

UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UNCY has more shares outstanding
UNCY has more shares outstanding than it did 5 years ago.
There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -6.24, we must say that UNCY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.24, UNCY is not doing good in the industry: 64.92% of the companies in the same industry are doing better.
There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.24
ROIC/WACCN/A
WACC9.04%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.28 indicates that UNCY should not have too much problems paying its short term obligations.
The Current ratio of UNCY (1.28) is worse than 84.45% of its industry peers.
A Quick Ratio of 1.28 indicates that UNCY should not have too much problems paying its short term obligations.
UNCY has a Quick ratio of 1.28. This is amonst the worse of the industry: UNCY underperforms 83.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

UNCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.20%, which is quite impressive.
UNCY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)59.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.8%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

UNCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.74%
EPS Next 2Y66.28%
EPS Next 3Y59.7%
EPS Next 5Y26.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UNCY. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 0.51, the valuation of UNCY can be described as very cheap.
UNCY's Price/Forward Earnings ratio is rather cheap when compared to the industry. UNCY is cheaper than 99.64% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, UNCY is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.51
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UNCY's earnings are expected to grow with 59.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.28%
EPS Next 3Y59.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UNCY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (8/1/2025, 8:08:18 PM)

After market: 4.4493 +0.25 (+5.94%)

4.2

-0.14 (-3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners52.5%
Inst Owner Change-0.03%
Ins Owners5.22%
Ins Owner Change0%
Market Cap53.63M
Analysts83.08
Price Target52.53 (1150.71%)
Short Float %N/A
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-2.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57.77%
Min EPS beat(2)-183.22%
Max EPS beat(2)67.68%
EPS beat(4)2
Avg EPS beat(4)-94.53%
Min EPS beat(4)-285.83%
Max EPS beat(4)67.68%
EPS beat(8)3
Avg EPS beat(8)-69%
EPS beat(12)3
Avg EPS beat(12)-55.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)719.32%
PT rev (3m)717.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)-641.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-30.36%
Revenue NY rev (3m)-21.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.51
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.22
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-5.1
EYN/A
EPS(NY)8.19
Fwd EY194.89%
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS0
BVpS0.58
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -119.44%
ROE -509%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-327.07%
ROA(5y)-432.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -6.24
F-Score4
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)7.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.8%
EPS Next Y80.74%
EPS Next 2Y66.28%
EPS Next 3Y59.7%
EPS Next 5Y26.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.38%
EBIT Next 3Y175.15%
EBIT Next 5YN/A
FCF growth 1Y-56.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.29%
OCF growth 3YN/A
OCF growth 5YN/A